{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T04:02:11Z","timestamp":1791086531837,"version":"4.1.0"},"reference-count":50,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2013,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            BMS-626529 is a novel small-molecule HIV-1 attachment inhibitor active against both CCR5- and CXCR4-tropic viruses. BMS-626529 functions by preventing gp120 from binding to CD4. A prodrug of this compound, BMS-663068, is currently in clinical development. As a theoretical resistance pathway to BMS-663068 could be the development of a CD4-independent phenotype, we examined the activity of BMS-626529 against CD4-independent viruses and investigated whether resistance to BMS-626529 could be associated with a CD4-independent phenotype. Finally, we evaluated whether cross-resistance exists between BMS-626529 and other HIV-1 entry inhibitors. Two laboratory-derived envelopes with a CD4-independent phenotype (one CXCR4 tropic and one CCR5 tropic), five envelopes from clinical isolates with preexisting BMS-626529 resistance, and several site-specific mutant BMS-626529-resistant envelopes were examined for their dependence on CD4 for infectivity or susceptibility to BMS-626529. Viruses resistant to other entry inhibitors (enfuvirtide, maraviroc, and ibalizumab) were also examined for susceptibility to BMS-626529. Both CD4-independent laboratory isolates retained sensitivity to BMS-626529 in CD4\n            <jats:sup>\u2212<\/jats:sup>\n            cells, while HIV-1 envelopes from viruses resistant to BMS-626529 exhibited no evidence of a CD4-independent phenotype. BMS-626529 also exhibited inhibitory activity against ibalizumab- and enfuvirtide-resistant envelopes. While there appeared to be some association between maraviroc resistance and reduced susceptibility to BMS-626529, an absolute correlation cannot be presumed, since some CCR5-tropic maraviroc-resistant envelopes remained sensitive to BMS-626529. Clinical use of the prodrug BMS-663068 is unlikely to promote resistance via generation of CD4-independent virus. No cross-resistance between BMS-626529 and other HIV entry inhibitors was observed, which could allow for sequential or concurrent use with different classes of entry inhibitors.\n          <\/jats:p>","DOI":"10.1128\/aac.00513-13","type":"journal-article","created":{"date-parts":[[2013,6,18]],"date-time":"2013-06-18T03:04:57Z","timestamp":1371524697000},"page":"4172-4180","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":73,"title":["Activity of the HIV-1 Attachment Inhibitor BMS-626529, the Active Component of the Prodrug BMS-663068, against CD4-Independent Viruses and HIV-1 Envelopes Resistant to Other Entry Inhibitors"],"prefix":"10.1128","volume":"57","author":[{"given":"Zhufang","family":"Li","sequence":"first","affiliation":[{"name":"Bristol-Myers Squibb, Research and Development, Wallingford, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nannan","family":"Zhou","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb, Research and Development, Wallingford, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongnian","family":"Sun","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb, Research and Development, Wallingford, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelanjana","family":"Ray","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb, Research and Development, Princeton, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Lataillade","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb, Research and Development, Wallingford, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George J.","family":"Hanna","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb, Research and Development, Princeton, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Krystal","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb, Research and Development, Wallingford, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200969010-00003"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0b013e32833ed6f4"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0b013e328322402e"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2009.07.022"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0803152"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035026"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq261"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00453-10"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.80.8.4017-4025.2006"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00759-10"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00426-12"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis432"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31829726f3"},{"key":"e_1_3_3_15_2","volume-title":"Genotypic and phenotypic correlates of virologic response to the attachment inhibitor BMS-626529 in a short-term monotherapy study with its prodrug BMS-663068, abstr 6, p A14","author":"Zhou N","year":"2012","unstructured":"ZhouNRayNHealyMLangleyDHwangCLatailladeMHannaGKrystalM. 2012. Genotypic and phenotypic correlates of virologic response to the attachment inhibitor BMS-626529 in a short-term monotherapy study with its prodrug BMS-663068, abstr 6, p A14. Abstr. 2012 Int. Wkshp. HIV Hepatitis Virus Drug Resist., Sitges, Spain."},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks067"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt018"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00639-12"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002101"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/prot.23005"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0307953101"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.11.5230-5239.2001"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.5.2041-2050.2001"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328308937c"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.3.1243-1255.2004"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.19.10528-10536.2003"},{"key":"e_1_3_3_27_2","volume-title":"XIX Int.","author":"Li Z","year":"2012","unstructured":"LiZZhouNSunYRayNLatailladeMHannaGJKrystalM. 2012. XIX Int. AIDS Conf., Washington, DC, 22 to 27 July 2012, poster TUPE015."},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja075204v"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2008.12.014"},{"key":"e_1_3_3_30_2","unstructured":"BurklyLCChisholmPLThomasDWRosaMDRosaJJ. February 1999. US patent 5 871 732."},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.73.10.8120-8126.1999"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.7.3435-3443.2001"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01109-10"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2009.0132"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.11.6359"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01313-07"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02237-10"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3182732746"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001432-200502000-00003"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.23.12078-12086.2002"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.73.12.10310-10319.1999"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01173-10"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-4-78"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.9.4628-4637.2004"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2006.11.004"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02006-06"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1832214100"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0b013e3283223d46"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1086\/589289"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01863-12"},{"key":"e_1_3_3_51_2","first-page":"156","article-title":"2011 update of the drug resistance mutations in HIV-1","volume":"19","author":"Johnson VA","year":"2011","unstructured":"JohnsonVACalvezVGunthardHFParedesRPillayDShaferRWensingAMRichmanDD. 2011. 2011 update of the drug resistance mutations in HIV-1. Top. Antivir. Med. 19:156\u2013164.","journal-title":"Top. Antivir. Med."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00513-13","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00513-13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:30:41Z","timestamp":1645482641000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00513-13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["10.1128\/AAC.00513-13"],"URL":"https:\/\/doi.org\/10.1128\/aac.00513-13","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"2013-03-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-06-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-08-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}